Alpha Synuclein Aggregation Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Alpha-synuclein aggregation inhibitors represent a promising therapeutic strategy for Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA) - collectively known as synucleinopathies. These compounds target the abnormal aggregation of the alpha-synuclein (α-syn) protein, which forms Lewy bodies and contributes to neuronal dysfunction and death. [1]
The rationale for targeting α-syn aggregation stems from: [2]
Current therapeutic approaches include: [3]
Several compounds have advanced to clinical trials, including Anle138b, UBL-0401, and antibody-based immunotherapies. [4]
Alpha-synuclein (α-syn) aggregation inhibitors represent a key therapeutic strategy for Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). These compounds aim to prevent or reverse the pathological aggregation of α-syn into Lewy bodies and glial cytoplasmic inclusions[1]. [5]
In synucleinopathies, α-syn undergoes a toxic gain-of-function transformation: [6]
Current therapies target various stages of this aggregation cascade.
Small molecules that bind to α-syn and prevent fibril formation:
Promote clearance of aggregated α-syn:
Reduce α-syn expression:
Inosine elevates urate, an endogenous antioxidant[2].
Nilotinib is a BCR-ABL inhibitor that induces autophagy[3].
GLP-1 receptor agonist with neuroprotective effects[4].
Anle138b is a small molecule aggregation inhibitor[5].
SynuClean-D is a small molecule identified through high-throughput screening[6].
ACI-35 (Affiris) is a liposome-based vaccine targeting phosphorylated α-syn at Ser129[7].
| Antibody | Target | Company | Phase |
|---|---|---|---|
| Prasinezumab (PRX002) | α-syn oligomers | Roche/Prothena | Phase 2 |
| Cinpanemab (BIIB054) | α-syn fibrils | Biogen | Phase 2 (failed) |
| MEDI1341 | α-syn | AstraZeneca/Prothena | Phase 1 |
Primary targets:
Focus on:
Key considerations:
α-syn aggregation inhibitors may combine with:
The study of Alpha Synuclein Aggregation Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Parkinson's Study Group. JAMA Neurology. 2020;77(4):427-438. 2020. ↩︎
Pagan F, et al. Movement Disorders. 2019. ↩︎
Athauda D, et al. The Lancet. 2017. ↩︎
Levin J, et al. Movement Disorders. 2019. ↩︎
Pujols J, et al. Proceedings of the National Academy of Sciences. 2018. ↩︎
Volc D, et al. The Lancet Neurology. 2020. ↩︎